Additional instruction is provided for brigatinib and ceritinib in so far that testing for ALK-positive NSCLC status should be performed by laboratories with demonstrated proficiency in the specific technology; there was no such reference in the case for ceritinib. Here, ALK is linked to non-small cell lung carcinoma.